Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

IDEAYA Biosciences, Inc. - Common Stock (NQ:IDYA)

37.87 +1.55 (+4.28%)
Streaming Delayed Price Updated: 3:48 PM EST, Jan 7, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Headline News about IDEAYA Biosciences, Inc. - Common Stock

< Previous 1 2 3 4 5 Next >
News headline image
IDEAYA Biosciences Inc (NASDAQ:IDYA) Shows Strong Technical Setup for Potential Breakout ↗
IDEAYA Biosciences (IDYA) shows strong technical health and a high-quality breakout setup, indicating potential for a continued advance. 
Via Chartmill
News headline image
SLB To Rally Around 44%? Here Are 10 Top Analyst Forecasts For Tuesday ↗
 
Via Benzinga
News headline image
Buying IDEAYA Might Be The Wrong IDYA Right Now ↗
IDEAYA Stock's Adhishthana.com cycle signals prolonged weakness after a failed Cakra, with underperformance likely until May 2029. 
Via Benzinga
News headline image
Alibaba To Rally Around 35%? Here Are 10 Top Analyst Forecasts For Tuesday ↗
 
Via Benzinga
News headline image
Unveiling 5 Analyst Insights On IDEAYA Biosciences ↗
 
Via Benzinga
News headline image
Demystifying IDEAYA Biosciences: Insights From 6 Analyst Reviews ↗
 
Via Benzinga
News headline image
The Analyst Verdict: IDEAYA Biosciences In The Eyes Of 6 Experts ↗
 
Via Benzinga
News headline image
12 Health Care Stocks Moving In Friday's After-Market Session ↗
 
Via Benzinga
News headline image
IDEAYA (IDYA) Q2 Net Loss Improves 27% ↗
Via The Motley Fool
Topics Intellectual Property
News headline image
This Royal Caribbean Cruises Analyst Begins Coverage On A Bullish Note; Here Are Top 4 Initiations For Tuesday ↗
 
Via Benzinga
News headline image
This Trade Desk Analyst Is No Longer Bullish; Here Are Top 5 Downgrades For Thursday ↗
 
Via Benzinga
News headline image
Recap: IDEAYA Biosciences Q4 Earnings ↗
 
Via Benzinga
News headline image
The Analyst Verdict: IDEAYA Biosciences In The Eyes Of 8 Experts ↗
 
Via Benzinga
News headline image
This NRG Energy Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Thursday ↗
 
Via Benzinga
News headline image
Jim Cramer Says This Tobacco Stock Is 'Undervalued' But He's Not Recommending It ↗
Altria Group is "undervalued," Cramer says. On Oct. 31, the company reported third-quarter adjusted earnings per share of $1.38. 
Via Benzinga
News headline image
This Cognex Analyst Is No Longer Bullish; Here Are Top 5 Downgrades For Tuesday ↗
 
Via Benzinga
News headline image
Ideaya Biosciences Stock Tumbles Despite Promising Data From Rare Eye Cancer Candidate ↗
IDEAYA Biosciences released interim Phase 2 data that shows promising tumor shrinkage and eye preservation rates. 
Via Benzinga
News headline image
Oracle To Rally Around 29%? Here Are 10 Top Analyst Forecasts For Tuesday ↗
 
Via Benzinga
News headline image
IDYA Stock Earnings: IDEAYA Biosciences Misses EPS for Q2 2024 ↗
IDYA stock results show that IDEAYA Biosciences missed analyst estimates for earnings per share the second quarter of 2024. 
Via InvestorPlace
News headline image
Week In Review: ImmuneOnco Out-Licenses Two Antibodies In $2 Billion Deal ↗
Shanghai ImmuneOnco Biopharma out-licensed global rites (ex-China) for two of its antibodies to Instil Bio of Dallas, Texas. ImmuneOnco will receive an upfront and near-term payments of $50 million,... 
Via Talk Markets
News headline image
Why SeaStar Medical Holding Shares Are Trading Lower By Around 34%? Here Are Other Stocks Moving In Wednesday's Mid-Day Session ↗
 
Via Benzinga
News headline image
Kura Sushi Posts Weak Q3 Results, Joins LegalZoom.com And Other Big Stocks Moving Lower In Wednesday's Pre-Market Session ↗
 
Via Benzinga
News headline image
Why Arhaus Shares Are Trading Lower By Around 8%? Here Are Other Stocks Moving In Monday's Mid-Day Session ↗
 
Via Benzinga
News headline image
IDEAYA Biosciences Highlights 'Encouraging' Preliminary Efficacy, Safety Profile For Patients With Hard-To-Treat Cancer ↗
IDEAYA Biosciences reports promising Phase 2 clinical data for IDE397 in MTAP-deletion urothelial and NSCLC patients. The study shows a 39% overall response rate, 94% disease control rate, and a... 
Via Benzinga
News headline image
Corning Increases Sales Forecast, Joins Morphic Holding, Lucid Group And Other Big Stocks Moving Higher On Monday ↗
 
Via Benzinga
News headline image
Why Ideaya Biosciences Just Made Its Most Bullish Move Since March ↗
The company is working on a treatment for cancers tied to a genetic alteration called MTAP deletion. 
Via Investor's Business Daily
News headline image
Why Paramount Global Shares Are Trading Higher By Around 8%; Here Are 20 Stocks Moving Premarket ↗
 
Via Benzinga
News headline image
IDYA Stock Earnings: IDEAYA Biosciences Misses EPS for Q1 2024 ↗
IDYA stock results show that IDEAYA Biosciences missed analyst estimates for earnings per share the first quarter of 2024. 
Via InvestorPlace
News headline image
Goldman Sachs Maintains Buy Rating for IDEAYA Biosciences: Here's What You Need To Know ↗
 
Via Benzinga
News headline image
Chart Of The Day: IDEAYA Biosciences - Oncology Biomedicine ↗
IDEAYA Biosciences, Inc., a synthetic lethality-focused precision medicine oncology company, focuses on the discovery and development of targeted therapeutics for patient populations selected using... 
Via Talk Markets
< Previous 1 2 3 4 5 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.